Ontology highlight
ABSTRACT:
SUBMITTER: Raskin S
PROVIDER: S-EPMC8526777 | biostudies-literature | 2021 Dec
REPOSITORIES: biostudies-literature
Raskin Scott S Van Pelt Stacey S Toner Keri K Balakrishnan Preethi Bala PB Dave Hema H Bollard Catherine M CM Yvon Eric E
Molecular therapy. Methods & clinical development 20211001
The synovial sarcoma X breakpoint 2 (SSX2) belongs to a multigene family of cancer-testis antigens and can be found overexpressed in multiple malignancies. Its restricted expression in immune-privileged normal tissues suggest that SSX2 may be a relevant target antigen for chimeric antigen receptor (CAR) therapy. We have developed a T cell receptor (TCR)-like antibody (Fab/3) that binds SSX2 peptide 41-49 (KASEKIFYV) in the context of HLA-A∗-0201. The sequence of Fab/3 was utilized to engineer a ...[more]